MarketPulse

drug delivery

11 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Eupraxia Pharmaceuticals Inc.

Eupraxia's EE Drug Hits Key Milestone With 90% Tissue Improvement in Phase Data

Eupraxia Pharmaceuticals reports positive Phase 1b/2a data for EP-104GI in eosinophilic esophagitis, showing 90% tissue improvement and strong safety profile.
EPRXbiotechdrug delivery
BenzingaBenzinga··Lekha Gupta

PRF Technologies Shares Plunge Despite Pharma Pivot and AI Solar Bet

PRFX stock tumbled Tuesday amid broader market weakness as investors remain skeptical the company's LayerBio and DeepSolar acquisitions can generate sustainable revenue.
PRFXstock declinesolar energy
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Serina Therapeutics Unveils PEG-Free LNP Technology at Industry Summit

Serina's Chief Development Officer to present novel POZ-based lipid nanoparticles that eliminate PEG immunogenicity issues, showing no antibody response in preclinical studies.
PFESERbiotechnologydrug delivery
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Nasus Pharma Advances NS002 to Pivotal Stage on Positive Phase 2 Data

Nasus Pharma reports positive Phase 2 data for NS002 intranasal epinephrine, planning pivotal study Q4 2026 with strong cash position through Q2 2027.
NSRXPhase 2 clinical trialPivotal Study
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

iDEL Therapeutics Names Ulbrich as Board Chair, Secures €9M Seed Round

iDEL Therapeutics appoints Dr. Claudia Ulbrich as Board Chair and secures €9M seed funding led by BiomedVC to advance its novel cancer drug delivery platform.
NVObiotechclinical development
BenzingaBenzinga··Na

Embecta to Acquire UK Drug-Delivery Specialist Owen Mumford for Up to £150M

Embecta agrees to acquire Owen Mumford Holdings for up to £150M, diversifying beyond insulin delivery into broader drug-delivery technologies.
EMBCacquisitionmanufacturing
BenzingaBenzinga··Vandana Singh

Aptar Promotes Insider Touya to CEO, Signaling Strategic Continuity Amid Mixed Signals

AptarGroup appoints Gael Touya as new CEO, replacing retiring Stephan Tanda. The internal promotion signals strategic continuity but stock shows mixed technical indicators.
ATRtechnical analysisleadership transition
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Eupraxia Raises $63.2M, Eyes 2028 as Cash-Runway Extends Despite Rising Losses

Eupraxia Pharmaceuticals closed $63.2M offering, boosting cash to $80.5M with runway through H2 2028. Q4 losses doubled to $16.7M amid clinical progress in eosinophilic esophagitis treatment.
EPRXpublic offeringdrug delivery
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Novo Nordisk Licenses Vivtex Technology for Oral Obesity and Diabetes Treatments

Novo Nordisk licenses Vivtex's oral drug-delivery technology for obesity and diabetes treatments, with potential $2.1B in milestone payments to develop oral alternatives to injectable biologics.
NVOpartnershipobesity treatment
BenzingaBenzinga··Globe Newswire

Eupraxia Pharmaceuticals Completes $63.2M Offering to Fund GI Disease Pipeline

Eupraxia Pharmaceuticals raises $63.2M to advance its GI disease pipeline, including EP-104GI trials for eosinophilic esophagitis and other gastrointestinal indications.
EPRXclinical trialspublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Eupraxia Pharmaceuticals Raises $55M Through Public Offering to Fund GI Pipeline

Eupraxia Pharmaceuticals raises $55M via public offering to advance EP-104GI for eosinophilic esophagitis through Phase 2/3 development and expand GI pipeline.
EPRXclinical trialspublic offering